Breast Cancer

A breast surgical oncologist at The University of Texas MD Anderson Cancer Center notes that while breast cancer screening can be delayed a few months, it should not be skipped altogether.

2020 has been a challenging year, especially for survivors and those with cancer, but you can look forward to the new year. You just have to imagine the possibilities.

Two sisters diagnosed with the same stage of breast cancer in the same spot three weeks apart take part in proton therapy trial, Mayo Clinic and Google Health partner to investigate the use of artificial intelligence in assisting with radiotherapy treatments and more from the weekly roundup of news and research happening in the cancer landscape.

In this episode of the “CURE Talks Cancer” podcast, we spoke with television journalist Katie Couric and Susan G. Komen CEO Paula Schneider about their experiences with cancer, and the advice they offered their pre-cancer selves.

A roundup of the latest news and updates for patients with breast cancer from CURE®.

October is Breast Cancer Awareness month and is deeply associated with the color pink, but it wasn't always like that. Here's how the breast cancer awareness movement began.

Treatments like kinase inhibitors are changing the options patient may have for when their breast cancer spreads to the brain.

The breast cancer patient advocacy movement that started in the 1950s pulled the disease out of the shadows, bringing patients’ options to light.

A group extends a hand to those affected by breast or reproductive cancers, especially younger previvors, patients and caregivers.

Paula Schneider, president and CEO of Susan G. Komen®, writes to her younger self on the lessons and challenges she faced as a patient with breast cancer.

Can mastectomy or lumpectomy be avoided in women with ductal carcinoma in situ?

Helping underserved women at the community level can be a crucial step toward reducing deaths from late-stage breast cancer. A grassroots initiative in Florida aims to contribute to that change and inspire the formation of similar groups.

Organized as a virtual event, the DONNA Foundation’s 2021 National Marathon to Finish Breast Cancer will allow participants to run in their neighborhoods — or on their treadmills.

Just one week of radiation therapy after surgery for early-stage breast cancer is as safe and effective as longer courses, researchers report.

Understanding cancer as a professional is one thing, but once you go through the journey it takes on a whole different understanding.

You may be surprised by what you can find in a hot shower, whether it be cancer or the discovery on how to live after treatment.

Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.

On social media, CURE® recently asked its readers to share their thoughts on the month of “Pinktober”.

Every October, pink ribbons pop up as a symbol of breast cancer awareness. This year, marketing strategies have changed due to the COVID-19 pandemic. One survivor offers some insight on those changes.

Remember, knowledge is power. The more information you have about your cancer, the less power it has over you.

Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.

The greatest obstacle facing men with breast cancer may be … ourselves.

“This randomized clinical trial found that compared with the conventional anthracycline and docetaxel regimen, the paclitaxel-plus-carboplatin regimen may be an alternative adjuvant chemotherapy strategy for patients with operable TNBC,” the authors wrote.

“In the field of triple-negative breast cancer, we're beginning to see some remarkable advances, mostly centering around the three paradigms that have become so attractive for the treatment of cancer: immunotherapy, targeted biologics and antibody-drug conjugates,” Dr. Howard A. “Skip” Burris, III said in an interview.

The Food and Drug Administration’s warning comes weeks after Genentech, the manufacturer of Tecentriq, issued a press release noting that the IMpassion131 trial failed to meet its primary endpoint of improving progression-free survival in patients with triple-negative breast cancer.